Wave Life Sciences Is Maintained at Sector Perform by RBC Capital
RBC Raises Price Target on WAVE Life Sciences to $7 From $5, Keeps Sector Perform Rating, Speculative Risk
B.Riley Financial Maintains Wave Life Sciences(WVE.US) With Buy Rating, Raises Target Price to $19
WAVE Life Sciences Analyst Ratings
J.P. Morgan Maintains Wave Life Sciences(WVE.US) With Buy Rating, Raises Target Price to $13
Mizuho Securities Maintains Wave Life Sciences(WVE.US) With Buy Rating
A Quick Look at Today's Ratings for Wave Life Sciences(WVE.US), With a Forecast Between $16 to $22
Wave Life Sciences (WVE) Gets a Buy From Truist Financial
Wave Life Sciences Is Maintained at Buy by HC Wainwright & Co.
Wave Life Sciences Price Target Raised to $22.00/Share From $15.00 by HC Wainwright & Co.
WAVE Life Sciences Analyst Ratings
Wave Life Sciences' WVE-N531 Shows Best-in-Class Potential in DMD Treatment, Justifying a Buy Rating
Wells Fargo Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $11
B.Riley Financial Initiates Wave Life Sciences(WVE.US) With Buy Rating, Announces Target Price $11
Wave Life Sciences: A Buy Rating on Groundbreaking RNA Therapies and Promising Clinical Trials
WAVE Life Sciences Analyst Ratings
J.P. Morgan Initiates Wave Life Sciences(WVE.US) With Buy Rating, Announces Target Price $10
JonesTrading Maintains Wave Life Sciences(WVE.US) With Buy Rating, Maintains Target Price $12
Truist Financial Maintains Wave Life Sciences(WVE.US) With Buy Rating
Truist Financial Reaffirms Their Buy Rating on Wave Life Sciences (WVE)